Advancements in targeted therapy for uterine cancer have been promising in improving treatment outcomes, reducing side effects, and enhancing the quality of life for patients. Targeted therapy is a type of cancer treatment that focuses on specific molecules or pathways involved in the growth and spread of cancer cells rather than broadly affecting rapidly dividing cells, as in traditional chemotherapy. Targeted therapies are drugs designed to target particular changes in cancer cells. They can be helpful for high risk or advanced uterine cancer.
One of the key advancements in targeted therapy is the ability to perform molecular profiling of uterine tumors. This involves analyzing the genetic and molecular characteristics of the tumor to identify specific mutations or alterations that can be targeted. This allows a personalized treatment approach, as each patient's cancer may have different molecular features.
Access Full Report @ https://www.databridgemarketresearch.com/fr/reports/europe-uterine-cancer-drug-market
Data Bridge Market Research analyzes that the Europe Uterine Cancer Drugs Market is expected to reach USD 1,251,870.80 thousand by 2030 from USD 684,672.98 thousand in 2022, growing at a CAGR of 8.4% during the forecast period of 2023 to 2030.
Key Findings of the Study
Growing R&D Activities for Uterine Cancer Treatment
Growing R&D activities for uterine cancer treatment represent a critical aspect of advancing medical science and improving patient outcomes. This increase in R&D activities reflects a deeper commitment to treat uterine cancer and develop more effective and targeted treatment strategies.
Researchers continually identify specific genetic mutations and molecular alterations associated with uterine cancer subtypes. These biomarkers help tailor treatment plans to individual patients and guide clinicians in selecting therapies that are more likely to be effective. For instance, identifying PTEN mutations in certain endometrial cancers has led to more personalized treatment options.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Thousand
|
|
Segments Covered
|
Cancer Type (Endometrial Cancer and Uterine Sarcoma), Treatment Type (Chemotherapy, Hormone Therapy, Targeted Therapy, Immunotherapy, and Others), Drug Type (Generics and Branded), Age Group (Adults and Geriatric), Route of Administration (Oral and Parenteral), End User (Hospitals, Cancer Centers, Specialty Clinics, and Others), Distribution Channel (Direct Tender, Retail Sales, and Others)
|
|
Countries Covered
|
Germany, France, U.K., Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland, and Rest of Europe
|
|
Market Players Covered
|
Baxter (U.S.), Eli Lilly and Company (U.S.), Hikma Pharmaceuticals PLC (U.K.), Sun Pharmaceutical Industries Ltd. (India), Viatris Inc. (U.S.), Sanofi (France), Teva Pharmaceuticals USA, Inc. (Israel), Amneal Pharmaceuticals LLC (U.S.), Merck & Co., Inc. (U.S.), GSK plc. (U.K.), Eisai Co., Ltd. (Japan), Pfizer Inc. (U.S.), and Getwell Oncology (India), among others
|
|
Data Points Covered in the Report
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
|
Segment Analysis
The Europe uterine cancer drugs market is segmented into seven notable segments based on cancer type, treatment type, drug type, age group, route of administration, end user, and distribution channel.
- On the basis of cancer type, the Europe uterine cancer drugs market is segmented into endometrial cancer and uterine sarcoma
In 2023, the endometrial cancer segment is expected to dominate the Europe uterine cancer drugs market
In 2023, the endometrial cancer segment is expected to dominate the market with an 83.28% market share due to the rising incidences of uterine cancer worldwide.
- On the basis of treatment type, the Europe uterine cancer drugs market is segmented into chemotherapy, immunotherapy, hormone therapy, targeted therapy, and others
In 2023, the chemotherapy segment is expected to dominate the Europe uterine cancer drugs market
In 2023, the chemotherapy segment is expected to dominate market with a 65.37% market share due to advancements in targeted therapy for uterine cancer.
- On the basis of drug type, the market is segmented into generics and branded. In 2023, the generics segment is expected to dominate the market with a 63.75% market share
- On the basis of age group, the market is segmented into geriatric and adults. In 2023, the geriatric segment is expected to dominate the market with a 73.42% market share
- On the basis of route of administration, the market is segmented into parenteral and oral. In 2023, the parenteral segment is expected to dominate the market with a 68.21% market share
- On the basis of end user, the market is segmented into hospitals, cancer centers, specialty clinics, and others. In 2023, the hospitals segment is expected to dominate the market with a 43.04% market share
- On the basis of distribution channel, the market is segmented into direct tender, retail sales, and others. In 2023, the direct tender segment is expected to dominate the market with a 54.88% market share
Major Players
Data Bridge Market Research analyzes Merck & Co., Inc. (U.S.), Sanofi (France), Eisai Co., Ltd. (Japan), Pfizer Inc. (U.S.), and Teva Pharmaceuticals USA, Inc. (Israel) as the major players operating in the Europe uterine cancer drugs market.
Market Developments
- In October 2023, Merck and Co., Inc. introduced effects from the Phase three KEYNOTE-A39 trial (additionally referred to as EV-302), which turned into collaboration with Seagen and Astellas, comparing KEYTRUDA, Merck’s anti-PD-1 therapy, plus Padcev (enfortumab vedotin-ejfv), an antibody-drug conjugate, as compared to chemotherapy (gemcitabine plus cisplatin or carboplatin) in sufferers with formerly untreated domestically superior or metastatic urothelial carcinoma. This helped the company to expand the application of their brand KEYTRUDA
- In October 2023, Eli Lilly and Company announced the acquisition of POINT Biopharma Global, Inc., which has radiopharmaceuticals in its pre-clinical and clinical pipeline used to target multiple types of cancer precisely. This acquisition helped the company to expand oncology capabilities into next-generation radioligand therapies
- In March 2023, Eisai Co., Ltd. announced the presentation of two abstracts at the Society of Gynaecologic Oncology (SGO) Women's Cancer 2023 Annual Meeting held in person in Tampa, Florida, and at the practice on March 25, 2023. Notable research to be featured in the Scientific Plenary IX: The Best of the Rest session includes a presentation of real-world outcomes and healthcare resource utilization in patients with recurrent or advanced endometrial carcinoma who were rechallenged with platinum chemotherapy in Europe. Also, presented data from the LEAP (LEnvatinib And Pembrolizumab) clinical program, which analyzed tumor response to the arm of lenvatinib (LENVIMA) and pembrolizumab (KEYTRUDA) in the pivotal Phase 3 study 309/KEYNOTE-775 in patients with advanced endometrial carcinoma following at least one previous platinum-based regimen in any setting. This initiative by the company was to raise awareness about LENVIMA treating endometrial cancer
- In March 2023, Teva Pharmaceuticals, a subsidiary of Teva Pharmaceutical USA, Inc. and NATCO Pharma Limited USA subsidiary, announced the launch of the generic version of Revlimid (lenalidomide capsules) in additional strengths of 2.5 mg and 20 mg. The companies launched four additional product strengths in the U.S. market in March 2022. At launch, the companies made all strengths of Lenalidomide available in the U.S. market
- In December 2022, Sanofi and Innate Pharma SA announced an expansion of their collaboration, with Sanofi licensing a Natural Killer (NK) cell engager program targeting B7H3 from Innate’s ANKETTM (Antibody-based NK Cell Engager Therapeutics) platform. Sanofi will also have the option to add up to two additional ANKETTM targets. Upon candidate selection, Sanofi will be responsible for all development, manufacturing, and commercialization. This collaboration helped expand Sanofi’s oncology portfolio in the market
Regional Analysis
Geographically, the countries covered in the Europe uterine cancer drugs market report are Germany, France, Italy, Spain, U.K., Switzerland, Netherlands, Russia, Turkey, Sweden, Belgium, and Rest of Europe.
As per Data Bridge Market Research analysis:
Germany is expected to dominate and is estimated to be the fastest-growing country in the Europe uterine cancer drugs market
Germany is expected to dominate the market in Europe owing to the high demand for uterine cancer drugs in the region and the rise in healthcare expenditure. Also it is estimated to be the fastest-growing country in the market due to the growing adoption of advanced targeted therapy and the launch of new products in the region.
For more detailed information about the Europe uterine cancer drugs market report, click here – https://www.databridgemarketresearch.com/fr/reports/europe-uterine-cancer-drug-market
